| pubmed-article:7044791 | pubmed:abstractText | Twenty-three patients with Peyronie's disease have been treated with the new anti-inflammatory metalloprotein drug orgotein, which exhibits pronounced superoxide dismutase activity. Administration was done into the indurated areas of the penis by a special syringe. Evaluation of signs and symptoms included measurement of the induration size and consistency as well as the degree of the deviation of the penis. The patients responded well to orgotein therapy, especially regarding the loss of pain on erection. On long term results also a diminishment of the induration size and penis deviation on erection was observed; the drug administered intraplaqueally was of outstanding safety. | lld:pubmed |
